P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS
A. McDonald,
J. L. R. Malherbe,
A. Kulasekararaj,
W. Füreder,
M. Griffin,
M. Cornpropst,
M. K. Farmer,
D. Kargl,
D. Collins,
W. Sheridan,
A. Risitano
Affiliations
A. McDonald
1 Netcare Pretoria East Hospital, Moreleta Park
J. L. R. Malherbe
2 University of the Free State, Bloemfontein, South Africa
A. Kulasekararaj
3 Kings College Hospital NHS Foundation Trust, London, United Kingdom
W. Füreder
4 Medical University of Vienna, Vienna, Austria
M. Griffin
5 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
M. Cornpropst
6 BioCryst Pharmaceuticals, Durham, United States of America
M. K. Farmer
6 BioCryst Pharmaceuticals, Durham, United States of America
D. Kargl
6 BioCryst Pharmaceuticals, Durham, United States of America
D. Collins
6 BioCryst Pharmaceuticals, Durham, United States of America
W. Sheridan
6 BioCryst Pharmaceuticals, Durham, United States of America
